secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALIMERA SCIENCES INC (—)
CIK:        0001267602
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001267602-24-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alimera Q4 net revenue +88% to $26.3M, positive EBITDA; guides >$105M for 2024; expands credit line by $5M
--------------------------------------------------------------------------------

- Q4 net revenue $26.3M (+88% YoY); full year $80.8M (+49%); net loss flat at $3.8M.
- Q4 adjusted EBITDA positive $5.0M vs $(1.2M) loss YoY; full year $8.7M vs $(7.9M) loss.
- Raises 2024 revenue guidance to >$105M and expects >20% adjusted EBITDA margin.
- U.S. net revenue $19.2M (+104%) driven by YUTIQ; international $7.1M (+52%).
- Amended loan facility: increased from $67.5M to $72.5M, $5M term loan funded; maturity April 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267602/000126760224000016/0001267602-24-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267602/000126760224000016/alim-20240306x8k.htm
  HTML page:      https://secwatch.observer/filing/0001267602-24-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer